Brief: Antengene Corp Announces Approval Of Clinical Trial Of ATG-016 For Treatment Of MDS In PRC
26/11/2020 01:19
Nov 26 (Reuters) - Antengene Corp Ltd 6996.HK :
* ANNOUNCES APPROVAL OF CLINICAL TRIAL OF ATG-016 FOR
TREATMENT OF
MYELODYSPLASTIC SYNDROMES IN PRC
Source text https://www1.hkexnews.hk/listedco/listconews/sehk/2020/1126/2020112600139.pdf
Further company coverage: 6996.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106